Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 285

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 285
---
R develops will prove to be accurate. DiamiR relies
on available statistical approaches and their derivatives for our data analysis needs. The tools currently available to DiamiR do not
guarantee a positive outcome.

JADBio is a vendor, similar
to other vendors with which DiamiR can work; any data DiamiR generate belongs to DiamiR. DiamiR’s contract with JADBio expired
in 2024 and DiamiR chose not to renew it at this time.

Develop proprietary LDTs
in DiamiR’s CLIA-certified laboratory. DiamiR has the capacity to process between about 3500 – 5500 tests per year. DiamiR
plans on introducing automation and robots into its lab operations to increase capacity, reduce turn-around-time (TAT), improve efficiency,
drive lower COGS, and reduce overhead expenses. DiamiR closely monitors FDA and congressional action around LDT statutes and will adjust
its strategy accordingly.

Drive early adoption of the
tests based on establishing collaborations with leading academic centers and industrial partners to ensure strong support for the tests
from Key Opinion Leaders (KOLs) at launch. DiamiR also aims to continue and to expand relationships with key associations, such as Alzheimer’s
Association, Alzheimer’s Drug Discovery Foundation (ADDF), Gates Ventures, and International Rett Syndrome Foundation (IRSF). DiamiR
has participated in, and plans on attending and presenting our work at key symposiums and conferences, such as Alzheimer’s Association
International Conference (AAIC), Clinical Trials on Alzheimer’s Disease (CTAD), AD/PD Alzheimer’s & Parkinson’s
Diseases Conference, Child Neurology Society (CNS) meeting and publish its work in high profile peer-reviewed journals.

Implement a robust commercial strategyaimed at securing coverage and contracting with Medicare and private payors. Publishing evidence of DiamiR’s tests’
validity and utility will drive its clinical work which in turn will power DiamiR’s reimbursement efforts.

<div align='center'>160</div>

Work closely with licensing and regulatory agencies to ensure that clinical validity and utility of the tests satisfy all necessary requirements and quality control
standards. These include maintaining licenses with States department of Health, CLIA and College of American Pathology (CAP).

Build a pipeline/portfolio of early detection and risk assessment tests in Brain health and other indications, including tests for Rett syndrome, and gastrointestinal
(GI) and pulmonary (lung) cancers.

In addition